170 related articles for article (PubMed ID: 37601688)
1. Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Powles T; Young A; Nimeiri H; Madison RW; Fine A; Zollinger DR; Huang Y; Xu C; Gjoerup OV; Aushev VN; Wu HT; Aleshin A; Carter C; Davarpanah N; Degaonkar V; Gupta P; Mariathasan S; Schleifman E; Assaf ZJ; Oxnard G; Hegde PS
Front Oncol; 2023; 13():1221718. PubMed ID: 37601688
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
[TBL] [Abstract][Full Text] [Related]
3. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Powles T; Assaf ZJ; Degaonkar V; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Sethi H; Aleshin A; Shi Y; Davarpanah N; Carter C; Bellmunt J; Mariathasan S
Eur Urol; 2024 Feb; 85(2):114-122. PubMed ID: 37500339
[TBL] [Abstract][Full Text] [Related]
4. Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection.
Nguyen Hoang TP; Nguyen TA; Tran NHB; Nguyen Hoang VA; Thi Dao HT; Tran VU; Nguyen YN; Nguyen AT; Nguyen Thi CT; Do Thi TT; Nguyen DS; Nguyen HN; Giang H; Tu LN
Front Mol Biosci; 2024; 11():1334808. PubMed ID: 38404964
[No Abstract] [Full Text] [Related]
5. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
6. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
[TBL] [Abstract][Full Text] [Related]
7. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
Eur Urol; 2024 May; ():. PubMed ID: 38811314
[TBL] [Abstract][Full Text] [Related]
8. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
[TBL] [Abstract][Full Text] [Related]
9. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients.
Chan HT; Nagayama S; Otaki M; Chin YM; Fukunaga Y; Ueno M; Nakamura Y; Low SK
Front Oncol; 2022; 12():1055968. PubMed ID: 36776372
[TBL] [Abstract][Full Text] [Related]
10. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Powles T; Assaf ZJ; Davarpanah N; Banchereau R; Szabados BE; Yuen KC; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Zimmermann BG; Sethi H; Aleshin A; Perdicchio M; Zhang J; Shames DS; Degaonkar V; Shen X; Carter C; Bais C; Bellmunt J; Mariathasan S
Nature; 2021 Jul; 595(7867):432-437. PubMed ID: 34135506
[TBL] [Abstract][Full Text] [Related]
11. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.
Zheng J; Qin C; Wang Q; Tian D; Chen Z
EBioMedicine; 2024 May; 103():105109. PubMed ID: 38614009
[TBL] [Abstract][Full Text] [Related]
13. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
14. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
Reinert T; Henriksen TV; Christensen E; Sharma S; Salari R; Sethi H; Knudsen M; Nordentoft I; Wu HT; Tin AS; Heilskov Rasmussen M; Vang S; Shchegrova S; Frydendahl Boll Johansen A; Srinivasan R; Assaf Z; Balcioglu M; Olson A; Dashner S; Hafez D; Navarro S; Goel S; Rabinowitz M; Billings P; Sigurjonsson S; Dyrskjøt L; Swenerton R; Aleshin A; Laurberg S; Husted Madsen A; Kannerup AS; Stribolt K; Palmelund Krag S; Iversen LH; Gotschalck Sunesen K; Lin CJ; Zimmermann BG; Lindbjerg Andersen C
JAMA Oncol; 2019 Aug; 5(8):1124-1131. PubMed ID: 31070691
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer.
Jiang J; Ye S; Xu Y; Chang L; Hu X; Ru G; Guo Y; Yi X; Yang L; Huang D
Front Oncol; 2020; 10():1220. PubMed ID: 32850360
[TBL] [Abstract][Full Text] [Related]
17. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
18. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
19. Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.
Nguyen HT; Nguyen TV; Nguyen Hoang VA; Tran DH; Le Trinh NA; Le MT; Nguyen Tran TA; Pham TH; Dinh TC; Nguyen TS; Nguyen The KC; Mai H; Chu MT; Pham DH; Nguyen XC; Ngo Ha TM; Nguyen DS; Nguyen DQ; Lu YT; Do Thi TT; Truong DK; Nguyen QT; Nguyen HN; Giang H; Tu LN
Front Oncol; 2022; 12():1069296. PubMed ID: 36578946
[TBL] [Abstract][Full Text] [Related]
20. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
